The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Dyskinesia LEAPS, 2012Development of L-745,870, a Selective D4 Receptor Antagonist, for the Treatment of Levodopa-induced Dyskinesia
Objective/Rationale:
In the 1980s and 90s a novel drug, L-745,870 was developed for the treatment of psychosis in schizophrenia. L-745,870 has excellent characteristics for a drug, and a selective... -
MJFF Research Grant, 2012Development of Nurr1-RXR Heterodimer Selective Agonists for Parkinson's Disease
Promising Outcomes of Original Grant:
We hypothesized that Nurr1 could be targeted indirectly with small molecules through other nuclear hormone receptors, and that such compounds would have... -
Alpha-synuclein Biology Challenge, 2012Alpha-synuclein as a Major Regulator of Iron Homeostasis
Objective/Rationale:
Alpha-synuclein is a key protein involved in Parkinson’s disease. Attempts have been made with drugs to lower the amount of this protein in the brain as a... -
LRRK2 in the Immune System, 2012Parkinson's and Inflammatory Bowel Diseases: Interaction in LRRK2 Transgenic Pre-clinical models
Objective/Rationale:
Mutations in LRRK2 are the most common cause of genetic PD. LRRK2 has also been recently linked to inflammatory bowel diseases (IBD), such as Crohn’s and ulcerative... -
Rapid Response Innovation Awards, 2012Effect of Tyrosine on Orthostatic Hypotension in Parkinson’s Disease
Objective/Rationale:
Orthostatic hypotension is a sudden drop in blood pressure (BP) when an individual changes position. Individuals with Parkinson’s disease (PD) commonly suffer from orthostatic... -
Rapid Response Innovation Awards, 2012Investigation of the Mechanisms Involved in Alpha-synuclein Secretion In Vivo
Objective/Rationale:
Extracellular alpha-synuclein appears to be central in the pathogenesis, and perhaps progression of PD. The mechanism(s) underling alpha-synuclein secretion are...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.